NCT03906331: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation |
|
|
| Approved for marketing | N/A | | Europe, Japan, US, RoW | Selpercatinib, LOXO-292, LY3527723 | Eli Lilly and Company, Eli Lilly and Company | Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration | | | | |
